May 20, 2013
Genetic copies of living people from embryos no longer science fiction
Jewz in the Newz by Nate Bloom :
The Kosher Gourmet by Cathy Pollak:
Jews Inducted into Rock Hall of Fame; Anton Yelchin co-stars in New "Trek" film; Kutcher (but not Kunis) visits Israel; Jewish TV Star Praises Jewish Rap Star
WARNING: This WALNUT CAKE WITH PRALINE FROSTING, perfect for afternoon coffee, is addicting
May 13, 2013
Rabbi Nathan Lopes Cardozo: Why the giving of the document that would permanently change the world could only be done in desolation
David G. Savage:
Church-state, literally? Supreme Court weighing public school graduation in a church
May 10, 2013
Rabbi Berel Wein: Be all that you should be
May 8, 2013
Peter Ford: Why China is welcoming both Israel's Netanyahu and Palestinians' Abbas
Obama administration quietly backs out of appeal over new contraceptive mandate
At Kerry-Putin meeting, US-Russia relations thaw --- a tad
The Kosher Gourmet by Leela Cyd Ross :
Almost too pretty to eat, this colorful salad with Sicilian inspiration will tickle the taste buds and delight your visual sensibility
May 6, 2013
May 3, 2013
Kids, kittens the Same?
With employee perks at struggling Internet pioneer Yahoo! it's hard to tell
Artificial kidney offers hope to patients tethered to a dialysis machine
April 29, 2013
Poland's new Jewish museum celebrates life, doesn't revisit Holocaust
Terrorism in America: Is US missing a chance to learn from failed plots?
Boston Bomber's 'Svengali' Revealed
Tiny satellites + cellphones = cheaper 'eyes in the sky' for NASA
April 26, 2013
Clifford D. May:
Defense in the Age of Jihadist Terrorism
Sharon Palmer, R.D.:
How to feel your best -- with plenty of energy, a healthy weight and optimal mental and physical function -- without driving yourself batty
April 24, 2013
Jewish World Review
June 29, 2009
/ 7 Tamuz 5769
No excuse for Dems' sticker shock on health care
Democrats' plans to pass major health care legislation have been stymied, at least for the moment, by the Congressional Budget Office's cost estimates. To the consternation and apparent surprise of leading Democrats, the CBO scored Senate Finance Chairman Max Baucus' latest offering at $1.6 trillion over 10 years, while it scored the completed sections of Sen. Christopher Dodd's bill at $1 trillion. Presumably, the incomplete sections would cost more.
The senators and the Obama administration might not have been so unpleasantly surprised had they paid closer attention to CBO Director Douglas Elmendorf's testimony to Baucus' committee delivered back on Feb. 25. Elmendorf, by the way, is no leftover hack from the Bush administration he is a Harvard-trained Ph.D. economist formerly at the Brookings Institution and appointed to his current position by congressional Democrats. My soundings indicate he is highly respected by economists associated with both political parties.
Elmendorf's February testimony, in crisp language punctures some of the balloons that have been sent aloft in Democrats' campaign talk about health care. One is the idea that since a lot of health care spending seems to be ineffective, it can be easily reduced by government action.
"The available evidence also suggests that a substantial share of spending on health care contributes little if anything to the overall health of the nation," Elmendorf said, agreeing with the first half of the proposition. Then he added, disagreeing with the second half, "But finding ways to reduce such spending without also affecting services that improve health will be difficult." It's like advertising: Half is wasted, but we're never sure which half.
Then there are the assurances by Office of Management and Budget Director Peter Orszag that by using the results of comparative-effectiveness research studies of the results of treatments in different regions and facilities we can easily identify the most cost-effective health care procedures and, using the power of government, force all practitioners to do things that way.
Elmendorf admitted that the benefits of such research "suggest a role for the government in funding research on the comparative effectiveness of treatments, in generating measures of quality, and in disseminating the results to doctors and patients." But then he threw some cold water on the proposition that such research could be used by government to jam down costs. "Absent stronger incentives to control costs and improve efficiency, the effect of information alone on spending will generally be limited."
And what about savings from moving away from "from fee-for-service design to providing stronger incentives to control costs or reward value"? In Elmendorf's view, "their precise effects are uncertain." He suggests testing options "to see whether they work as intended or to determine which design features work best." And maybe we should reform Medicare before we try to reshape the entire health care private sector. "Changes made in the Medicare program can also stimulate broader improvements in the health sector."
What about improved information technology? "Requiring that hospitals adopt electronic health records would reduce their costs for treating Medicare patients, but the program's payment rates would have to be reduced in order for the federal government to capture much of those savings." Preventive care? "Those efforts may still fail to generate net reductions in spending on health care because the number of people receiving the services is generally much larger than the number who would avoid expensive treatments as a result."
There are two more general problems, one of which Elmendorf spotlights: "Studies attribute the bulk of cost growth to the development of new treatments and other medical technologies," and so "reducing or slowing spending over the long term would probably require decreasing the pace of adopting new treatments and procedures or limiting the breadth of their application." If you pay less, you get less.
Second, and perhaps beyond the ambit of a data-driven CBO director, is the more general observation that the cost projections for government-run programs like Medicare and Medicare tend to come in low, while the cost projections for programs involving private-sector competition like the 2003 Medicare prescription drug benefit have turned out to be high.
Private-sector competition produces efficiencies and innovations that government bureaucracies almost never produce and can seldom keep up with. As Democrats scamper to reduce the projected costs of their health care bills, the rest of us might want to keep that in mind.
Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". Sign up for the daily JWR update. It's free. Just click here.
Comment by clicking here.
JWR contributor Michael Barone is senior political analyst for The Washington Examiner.
Michael Barone Archives
© 2009, Washington Examiner; DISTRIBUTED BY CREATORS SYNDICATE INC.
Richard Z. Chesnoff
Frank J. Gaffney
Victor Davis Hanson
A. Barton Hinkle
Judge A. Napolitano
Cokie & Steve Roberts
Debra J. Saunders
J. D. Crowe
Ask Doctor K